Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Beximco Pharmaceuticals Limited Sponsored GDR RegS (GB:BXP)
LSE:BXP
Beximco Pharmaceuticals Limited Sponsored GDR RegS (BXP) Share Price & Analysis
2 Followers
BXP Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range31.52p - 45.00p
Previous Close37.5p
Volume1.08K
Average Volume (3M)52.88K
Market Cap
$52.82B
Enterprise Value60.11B
Total Cash (Recent Filing)$938.65M
Total Debt (Recent Filing)$10.07B
Price to Earnings (P/E)4.3
Beta0.07
Next Earnings
Nov 07, 2024EPS EstimateN/A
Last Dividend Ex-Date
Nov 10, 2023Dividend Yield5.71%
Share Statistics
EPS (TTM)0.09
Shares Outstanding446,112,089
10 Day Avg. Volume60,967
30 Day Avg. Volume52,878
Standard Deviation0.14
R-Squared0.12
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.57
Price to Sales (P/S)1.24
Price to Cash Flow (P/CF)2.50
P/FCF Ratio3.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.61
Enterprise Value/Gross Profit4.14
Enterprise Value/Ebitda8.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Beximco Pharmaceuticals Limited Sponsored GDR RegS News
PremiumCompany Announcements
Beximco Pharma Reports Strong Growth Amid ChallengesBXP FAQ
What was Beximco Pharmaceuticals Limited Sponsored GDR RegS’s price range in the past 12 months?
Beximco Pharmaceuticals Limited Sponsored GDR RegS lowest share price was 31.52p and its highest was 45.00p in the past 12 months.
What is Beximco Pharmaceuticals Limited Sponsored GDR RegS’s market cap?
Currently, no data Available
When is Beximco Pharmaceuticals Limited Sponsored GDR RegS’s upcoming earnings report date?
Beximco Pharmaceuticals Limited Sponsored GDR RegS’s upcoming earnings report date is Nov 07, 2024 which is in 186 days.
How were Beximco Pharmaceuticals Limited Sponsored GDR RegS’s earnings last quarter?
Beximco Pharmaceuticals Limited Sponsored GDR RegS released its earnings results on Apr 30, 2024. The company reported 0.022p earnings per share for the quarter, beating the consensus estimate of N/A by 0.022p.
Is Beximco Pharmaceuticals Limited Sponsored GDR RegS overvalued?
According to Wall Street analysts Beximco Pharmaceuticals Limited Sponsored GDR RegS’s price is currently Overvalued.
Does Beximco Pharmaceuticals Limited Sponsored GDR RegS pay dividends?
Beximco Pharmaceuticals Limited Sponsored GDR RegS pays a Annually dividend of 2.09p which represents an annual dividend yield of 5.71%. See more information on Beximco Pharmaceuticals Limited Sponsored GDR RegS dividends here
What is Beximco Pharmaceuticals Limited Sponsored GDR RegS’s EPS estimate?
Beximco Pharmaceuticals Limited Sponsored GDR RegS’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beximco Pharmaceuticals Limited Sponsored GDR RegS have?
Beximco Pharmaceuticals Limited Sponsored GDR RegS has 446,112,100 shares outstanding.
What happened to Beximco Pharmaceuticals Limited Sponsored GDR RegS’s price movement after its last earnings report?
Beximco Pharmaceuticals Limited Sponsored GDR RegS reported an EPS of 0.022p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Beximco Pharmaceuticals Limited Sponsored GDR RegS?
Currently, no hedge funds are holding shares in GB:BXP
---
Beximco Pharmaceuticals Limited Sponsored GDR RegS Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.54%
12-Months-Change
Fundamentals
Return on Equity
11.81%
Trailing 12-Months
Asset Growth
-2.44%
Trailing 12-Months
Company Description
Beximco Pharmaceuticals Limited Sponsored GDR RegS
Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.
---
Technical Analysis
---